Información del artículo
Abstract
Objective
Due to the amount and quality variability regarding the use of biologic therapy (BT) in psoriatic arthritis (PsA) patients, the Spanish Society of Rheumatology (SER) has promoted the generation of recommendations based on the best evidence available. These recommendations should serve as reference to rheumatologists and those involved in the treatment of patients with PsA, who are using, or about to use BT.
MethodsRecommendations were developed following a nominal group methodology and based on systematic reviews. The level of evidence and degree of recommendation was classified according to the model proposed by the Center for Evidence Based Medicine at Oxford. The level of agreement was established through Delphi technique.
ResultsWe have produced recommendations for the use of TB currently available for PsA in our country. These recommendations include disease assessment, treatment objectives, therapeutic scheme and switching.
ConclusionsWe present an update on the SER recommendations for the use of BT in patients with PsA.
Keywords:
Consensus
Recommendations
Guide
Biologic therapy
Psoriatic arthritis
Resumen
Objetivo
Dada la gran cantidad de información actual sobre el uso de terapias biológicas (TB) en la artritis psoriásica (APs), y la variabilidad de la misma en cuanto a su calidad, desde la Sociedad Española de Reumatología (SER) se ha impulsado la generación de recomendaciones basadas en la mejor evidencia posible. Éstas deben servir de referencia para reumatólogos e implicados en el tratamiento de APs que vayan a utilizar o consideren la utilización de TB.
MétodosLas recomendaciones se emitieron siguiendo la metodología de grupos nominales y basadas en revisiones sistemáticas. El nivel de evidencia y el grado de recomendación se clasificaron según el modelo del Center for Evidence Based Medicine de Oxford y el grado de acuerdo se extrajo por técnica Delphi.
ResultadosSe realizan recomendaciones sobre el uso de las TB disponibles en la actualidad en nuestro país para el tratamiento de la APs. Estas recomendaciones incluyen la evaluación de la enfermedad, objetivos del tratamiento, esquema terapéutico y cambios en el mismo.
ConclusionesSe presentan las actualizaciones a las recomendaciones SER para el uso de TB en pacientes con APs.
Palabras clave:
Consenso
Recomendaciones
Guía
Terapia biológica
Artritis psoriásica
El Texto completo está disponible en PDF
References
[2.]
W. Taylor, D. Gladman, P. Helliwell, A. Marchesoni, P. Mease, H. Mielants.
Classification criteria for psoriatic arthritis: development of new criteria from a large international study.
Arthritis Rheum, 54 (2006), pp. 2665-2673
[3.]
A.P. Anandarajah, C.T. Ritchlin.
The diagnosis and treatment of early psoriatic arthritis.
Nat Rev Rheumatol, 5 (2009), pp. 634-641
[4.]
D.D. Gladman, P.J. Mease, V. Strand, P. Healy, P.S. Helliwell, O. Fitzgerald, et al.
Consensus on a core set of domains for psoriatic arthritis.
J Rheumatol, 34 (2007), pp. 1167-1170
[5.]
R.S. Stern, T. Nijsten, S.R. Feldman, D.J. Margolis, T. Rolstad.
Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction.
J Investig Dermatol Symp Proc, 9 (2004), pp. 136-139
[7.]
P.S. Helliwell, W.J. Taylor.
Classification and diagnostic criteria for psoriatic arthritis.
Ann Rheum Dis, 64 (2005), pp. ii3-ii8
[8.]
T. O’Neill, A.J. Silman.
Psoriatic arthritis Historical background and epidemiology.
Baillieres Clin Rheumatol, 8 (1994), pp. 245-261
[9.]
M.K. Soderlin, O. Borjesson, H. Kautiainen, T. Skogh, M. Leirisalo-Repo.
Annual incidence of inflammatory joint diseases in a population based study in southern Sweden.
Ann Rheum Dis, 61 (2002), pp. 911-915
[10.]
I.N. Bruce.
Psoriasis arthritis: clinical features.
Rheumatology, 3rd ed, pp. 1241-1252
[11.]
E. Savolainen, O. Kaipiainen-Seppanen, L. Kroger, R. Luosujarvi.
Total incidence and distribution of inflammatory joint diseases in a defined population: results from the Kuopio 2000 arthritis survey.
J Rheumatol, 30 (2003), pp. 2460-2468
[12.]
M. Shbeeb, K.M. Uramoto, L.E. Gibson, W.M. O’Fallon, S.E. Gabriel.
The epidemiology of psoriatic arthritis in Olmsted County, Minnesota, USA 1982–1991.
J Rheumatol, 27 (2000), pp. 1247-1250
[13.]
D. Kane, L. Stafford, B. Bresnihan, O. FitzGerald.
A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience.
Rheumatology (Oxford), 42 (2003), pp. 1460-1468
[14.]
D.D. Gladman, E.N. Hing, C.T. Schentag, R.J. Cook.
Remission in psoriatic arthritis.
J Rheumatol, 28 (2001), pp. 1045-1048
[15.]
D.D. Gladman, V.T. Farewell, K. Wong, J. Husted.
Mortality studies in psoriatic arthritis: results from a single outpatient center. II. Prognostic indicators for death.
Arthritis Rheum, 41 (1998), pp. 1103-1110
[16.]
K. Wong, D.D. Gladman, J. Husted, J.A. Long, V.T. Farewell.
Mortality studies in psoriatic arthritis: results from a single outpatient clinic. I. Causes and risk of death.
Arthritis Rheum, 40 (1997), pp. 1868-1872
[17.]
C.T. Ritchlin, A. Kavanaugh, D.D. Gladman, P.J. Mease, P. Helliwell, W.H. Boehncke, et al.
Treatment recommendations for psoriatic arthritis.
Ann Rheum Dis, 68 (2009), pp. 1387-1394
[18.]
U.A. Walker, M. Uhl, S.M. Weiner, K. Warnatz, A. Lange-Nolde, H. Dertinger, et al.
Analgesic and disease modifying effects of interferential current in psoriatic arthritis.
Rheumatol Int, 26 (2006), pp. 904-907
[19.]
A.F. Kavanaugh, C.T. Ritchlin.
Systematic review of treatments for psoriatic arthritis: an evidence based approach and basis for treatment guidelines.
J Rheumatol, 33 (2006), pp. 1417-1421
[20.]
E.R. Soriano, N.J. McHugh.
Therapies for peripheral joint disease in psoriatic arthritis. A systematic review.
J Rheumatol, 33 (2006), pp. 1422-1430
[21.]
P.S. Helliwell.
Therapies for dactylitis in psoriatic arthritis. A systematic review.
J Rheumatol, 33 (2006), pp. 1439-1441
[22.]
C.T. Ritchlin.
Therapies for psoriatic enthesopathy. A systematic review.
J Rheumatol, 33 (2006), pp. 1435-1438
[23.]
L. Eder, V. Chandran, J. Ueng, S. Bhella, K.A. Lee, P. Rahman, et al.
Predictors of response to intra-articular steroid injection in psoriatic arthritis.
Rheumatology (Oxford), 49 (2010), pp. 1367-1373
[24.]
P. Nash.
Assessment and treatment of psoriatic spondylitis.
Curr Rheumatol Rep, 11 (2009), pp. 278-283
[25.]
J.L. Fernandez-Sueiro, A. Willisch, S. Pertega-Diaz, J.A. Tasende, C. Fernandez-Lopez, F. Galdo, et al.
Evaluation of ankylosing spondylitis spinal mobility measurements in the assessment of spinal involvement in psoriatic arthritis.
Arthritis Rheum, 61 (2009), pp. 386-392
[26.]
V. Chandran, J. Barrett, C.T. Schentag, V.T. Farewell, D.D. Gladman.
Axial psoriatic arthritis: update on a longterm prospective study.
J Rheumatol, 36 (2009), pp. 2744-2750
[27.]
Sociedad Española de Reumatología. Guía de práctica clínica sobre el manejo de los pacientes con espondiloartritis (ESPOGUIA) 2010.
[28.]
K. Fitch, S.J. Bernstein, M.D. Aguilar, B. Burnand, J.R. LaCalle, P. Lazaro, et al.
The RAND/UCLA Appropriateness Method User's Manual.
RAND, (2001),
[29.]
E. Collantes, J.L. Fernández Sueiro, R. García-Vicuña, J. Gratacós, J. Mulero, S. Muñoz Fernández, et al.
Documento de consenso: Actualización del Consenso de la Sociedad Española de Reumatología sobre el uso de antagonistas del TNF en las espondiloartritis, incluida la artritis psoriásica.
Reumatol Clin, 3 (2007), pp. 60-70
[30.]
CEBM CfEBM. Oxford Centre for Evidence-based Medicine - Levels of Evidence (March 2009). 2009
[31.]
K.A. Papp, S. Tyring, M. Lahfa, J. Prinz, C.E. Griffiths, A.M. Nakanishi, et al.
A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction.
Br J Dermatol, 152 (2005), pp. 1304-1312
[32.]
C.E. Antoni, A. Kavanaugh, B. Kirkham, Z. Tutuncu, G.R. Burmester, U. Schneider, et al.
Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT).
Arthritis Rheum, 52 (2005), pp. 1227-1236
[33.]
A. Kavanaugh, G.G. Krueger, A. Beutler, C. Guzzo, B. Zhou, L.T. Dooley, et al.
Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial.
Ann Rheum Dis, 66 (2007), pp. 498-505
[34.]
A. Menter, S.K. Tyring, K. Gordon, A.B. Kimball, C.L. Leonardi, R.G. Langley, et al.
Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial.
J Am Acad Dermatol, 58 (2008), pp. 106-115
[35.]
M. Papoutsaki, M.S. Chimenti, A. Costanzo, M. Talamonti, A. Zangrilli, A. Giunta, et al.
Adalimumab for severe psoriasis and psoriatic arthritis: an open-label study in 30 patients previously treated with other biologics.
J Am Acad Dermatol, 57 (2007), pp. 269-275
[36.]
A. Kavanaugh, I. McInnes, P. Mease, G.G. Krueger, D. Gladman, J. Gomez-Reino, et al.
Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study.
Arthritis Rheum, 60 (2009), pp. 976-986
[37.]
P.J. Mease, D.D. Gladman, C.T. Ritchlin, E.M. Ruderman, S.D. Steinfeld, E.H. Choy, et al.
Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial.
Arthritis Rheum, 52 (2005), pp. 3279-3289
[38.]
A.A. Saad, D.P. Symmons, P.R. Noyce, D.M. Ashcroft.
Risks and benefits of tumor necrosis factor-alpha inhibitors in the management of psoriatic arthritis: systematic review and metaanalysis of randomized controlled trials.
J Rheumatol, 35 (2008), pp. 883-890
[39.]
N. Woolacott, Y. Bravo Vergel, N. Hawkins, A. Kainth, Z. Khadjesari, K. Misso, et al.
Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation.
Health Technol Assess, 10 (2006), pp. 1-239
[40.]
N.F. Woolacott, Z.C. Khadjesari, I.N. Bruce, R.P. Riemsma.
Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review.
Clin Exp Rheumatol, 24 (2006), pp. 587-593
[41.]
C.E. Antoni, A. Kavanaugh, D. van der Heijde, A. Beutler, G. Keenan, B. Zhou, et al.
Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT).
J Rheumatol, 35 (2008), pp. 869-876
[42.]
D.D. Gladman, P.J. Mease, C.T. Ritchlin, E.H. Choy, J.T. Sharp, P.A. Ory, et al.
Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial.
Arthritis Rheum, 56 (2007), pp. 476-488
[43.]
P.J. Mease, P. Ory, J.T. Sharp, C.T. Ritchlin, F. Van den Bosch, F. Wellborne, et al.
Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT).
Ann Rheum Dis, 68 (2009), pp. 702-709
[44.]
P.J. Mease, J.M. Woolley, A. Singh, W. Tsuji, M. Dunn, C.F. Chiou.
Patient-reported outcomes in a randomized trial of etanercept in psoriatic arthritis.
J Rheumatol, 37 (2010), pp. 1221-1227
[45.]
P.J. Mease, A.J. Kivitz, F.X. Burch, E.L. Siegel, S.B. Cohen, P. Ory, et al.
Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2years of treatment with etanercept.
J Rheumatol, 33 (2006), pp. 712-721
[46.]
Saougou I, Markatseli TE, Papagoras C, Voulgari PV, Alamanos Y, Drosos AA. Sustained Clinical Response in Psoriatic Arthritis Patients Treated with Anti-TNF Agents: A 5-year Open-Label Observational Cohort Study. Semin Arthritis Rheum. 2010. [In press].
[47.]
K. de Vlam, R.J. Lories.
Efficacy, effectiveness and safety of etanercept in monotherapy for refractory psoriatic arthritis: a 26-week observational study.
Rheumatology (Oxford), 45 (2006), pp. 321-324
[48.]
A. Kavanaugh, C. Antoni, G.G. Krueger, S. Yan, M. Bala, L.T. Dooley, et al.
Infliximab improves health related quality of life and physical function in patients with psoriatic arthritis.
Ann Rheum Dis, 65 (2006), pp. 471-477
[49.]
D.D. Gladman, P.J. Mease, M.A. Cifaldi, R.J. Perdok, E. Sasso, J. Medich.
Adalimumab improves joint-related and skin-related functional impairment in patients with psoriatic arthritis: patient-reported outcomes of the Adalimumab Effectiveness in Psoriatic Arthritis Trial.
Ann Rheum Dis, 66 (2007), pp. 163-168
[50.]
D.D. Gladman, P.J. Mease, E.H. Choy, C.T. Ritchlin, R.J. Perdok, E.H. Sasso.
Risk factors for radiographic progression in psoriatic arthritis: subanalysis of the randomized controlled trial ADEPT.
Arthritis Res Ther, 12 (2010), pp. R113
[51.]
U. Fiocco, P. Sfriso, F. Oliviero, P. Roux-Lombard, E. Scagliori, L. Cozzi, et al.
Synovial effusion and synovial fluid biomarkers in psoriatic arthritis to assess intraarticular tumor necrosis factor-alpha blockade in the knee joint.
Arthritis Res Ther, 12 (2010), pp. R148
[52.]
E. Cauza, U. Hanusch-Enserer, K. Frischmuth, B. Fabian, A. Dunky, K. Kostner.
Short-term infliximab therapy improves symptoms of psoriatic arthritis and decreases concentrations of cartilage oligomeric matrix protein.
J Clin Pharm Ther, 31 (2006), pp. 149-152
[53.]
M.S. Heiberg, B.Y. Nordvag, K. Mikkelsen, E. Rodevand, C. Kaufmann, P. Mowinckel, et al.
The comparative effectiveness of tumor necrosis factor-blocking agents in patients with rheumatoid arthritis and patients with ankylosing spondylitis: a six-month, longitudinal, observational, multicenter study.
Arthritis Rheum, 52 (2005), pp. 2506-2512
[54.]
C. Antoni, G.G. Krueger, K. De Vlam, C. Birbara, A. Beutler, C. Guzzo, et al.
Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial.
Ann Rheum Dis, 64 (2005), pp. 1150-1157
[55.]
P.J. Mease, A.J. Kivitz, F.X. Burch, E.L. Siegel, S.B. Cohen, P. Ory, et al.
Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression.
Arthritis Rheum, 50 (2004), pp. 2264-2272
[56.]
C. Fiehn, K. Andrassy.
Case number 29: hitting three with one strike: rapid improvement of psoriatic arthritis, psoriatic erythroderma, and secondary renal amyloidosis by treatment with infliximab (Remicade).
Ann Rheum Dis, 63 (2004), pp. 232
[57.]
A.P. Anandarajah, E.M. Schwarz, S. Totterman, J. Monu, C.Y. Feng, T. Shao, et al.
The effect of etanercept on osteoclast precursor frequency and enhancing bone marrow oedema in patients with psoriatic arthritis.
Ann Rheum Dis, 67 (2008), pp. 296-301
[58.]
E. Spanakis, P. Sidiropoulos, J. Papadakis, E. Ganotakis, G. Katsikas, S. Karvounaris, et al.
Modest but sustained increase of serum high density lipoprotein cholesterol levels in patients with inflammatory arthritides treated with infliximab.
J Rheumatol, 33 (2006), pp. 2440-2446
[59.]
B. Strober, C. Teller, P. Yamauchi, J.L. Miller, M. Hooper, Y.C. Yang, et al.
Effects of etanercept on C-reactive protein levels in psoriasis and psoriatic arthritis.
Br J Dermatol, 159 (2008), pp. 322-330
[60.]
D.D. Gladman.
Adalimumab, etanercept and infliximab are equally effective treatments for patients with psoriatic arthritis.
Nat Clin Pract Rheumatol, 4 (2008), pp. 510-511
[61.]
A.A. Saad, D.M. Ashcroft, K.D. Watson, K.L. Hyrich, P.R. Noyce, D.P. Symmons.
Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register.
Arthritis Res Ther, 11 (2009), pp. R52
[62.]
C. Delaunay, V. Farrenq, A. Marini-Portugal, J.D. Cohen, X. Chevalier, P. Claudepierre.
Infliximab to etanercept switch in patients with spondyloarthropathies and psoriatic arthritis: preliminary data.
J Rheumatol, 32 (2005), pp. 2183-2185
[63.]
M. Rudwaleit, F. Van den Bosch, M. Kron, S. Kary, H. Kupper.
Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy.
Arthritis Res Ther, 12 (2010), pp. R117
[64.]
W. Sterry, J.P. Ortonne, B. Kirkham, O. Brocq, D. Robertson, R.D. Pedersen, et al.
Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial.
BMJ, 340 (2010), pp. c147
[65.]
W.P. Maksymowych, G.S. Jhangri, R.G. Lambert, C. Mallon, H. Buenviaje, E. Pedrycz, et al.
Infliximab in ankylosing spondylitis: a prospective observational inception cohort analysis of efficacy and safety.
J Rheumatol, 29 (2002), pp. 959-965
[66.]
S. Keeling, A. Oswald, A.S. Russell, W.P. Maksymowych.
Prospective observational analysis of the efficacy and safety of low-dose (3mg/kg) infliximab in ankylosing spondylitis: 4-year followup.
J Rheumatol, 33 (2006), pp. 558-561
[67.]
J. Brandt, H. Haibel, J. Reddig, J. Sieper, J. Braun.
Successful short term treatment of severe undifferentiated spondyloarthropathy with the anti-tumor necrosis factor-alpha monoclonal antibody infliximab.
J Rheumatol, 29 (2002), pp. 118-122
[68.]
A. Kavanaugh, C.E. Antoni, D. Gladman, S. Wassenberg, B. Zhou, A. Beutler, et al.
The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): results of radiographic analyses after 1 year.
Ann Rheum Dis, 65 (2006), pp. 1038-1043
[69.]
J. Gratacos, E. Casado, J. Real, J.C. Torre-Alonso.
Prediction of major clinical response (ACR50) to infliximab in psoriatic arthritis refractory to methotrexate.
Ann Rheum Dis, 66 (2007), pp. 493-497
[70.]
M. Feletar, J.E. Brockbank, C.T. Schentag, V. Lapp, D.D. Gladman.
Treatment of refractory psoriatic arthritis with infliximab: a 12 month observational study of 16 patients.
Ann Rheum Dis, 63 (2004), pp. 156-161
[71.]
Behm BW, Bickston SJ. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev. 2008(1):CD006893.
[72.]
S. Guignard, L. Gossec, C. Salliot, A. Ruyssen-Witrand, M. Luc, M. Duclos, et al.
Efficacy of tumour necrosis factor blockers in reducing uveitis flares in patients with spondylarthropathy: a retrospective study.
Ann Rheum Dis, 65 (2006), pp. 1631-1634
[73.]
C. Salvarani, F. Cantini, I. Olivieri, P. Macchioni, A. Padula, L. Niccoli, et al.
Efficacy of infliximab in resistant psoriatic arthritis.
Arthritis Rheum., 49 (2003), pp. 541-545
[74.]
D. van der Heijde, A. Kavanaugh, D.D. Gladman, C. Antoni, G.G. Krueger, C. Guzzo, et al.
Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis through one year of treatment: Results from the induction and maintenance psoriatic arthritis clinical trial 2.
Arthritis Rheum, 56 (2007), pp. 2698-2707
[75.]
M. Covelli, C. Scioscia, F. Iannone, G. Lapadula.
Repeated infusions of low-dose infliximab plus methotrexate in psoriatic arthritis: immediate benefits are not maintained after discontinuation of infliximab.
Clin Exp Rheumatol, 23 (2005), pp. 145-151
[76.]
M.C. Genovese, P.J. Mease, G.T. Thomson, A.J. Kivitz, R.J. Perdok, M.A. Weinberg, et al.
Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy.
J Rheumatol, 34 (2007), pp. 1040-1050
[77.]
A.P. Anandarajah, P. Ory, D. Salonen, C. Feng, R.L. Wong, C.T. Ritchlin.
Effect of adalimumab on joint disease: features of patients with psoriatic arthritis detected by magnetic resonance imaging.
Ann Rheum Dis, 69 (2010), pp. 206-209
[78.]
A. Kavanaugh, P. Mease, G.G. Krueger, D. Gladman, J. Zrubek, A. Beutler.
Golimumab, a new human TNF alpha antibody, administered subcutaneously every 4weeks, in psoriatic arthritis patients: 104 week efficacy and safety results of the randomized, placebo-controlled GO-REVEAL study.
Arthritis Rheum, 60 (2009), pp. S189-S190
[79.]
L.C. Coates, J. Fransen, P.S. Helliwell.
Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment.
Ann Rheum Dis, 69 (2010), pp. 48-53
[80.]
T.P. Saber, C.T. Ng, G. Renard, B.M. Lynch, E. Pontifex, C.A. Walsh, et al.
Remission in psoriatic arthritis: is it possible and how can it be predicted?.
Arthritis Res Ther, 12 (2010), pp. R94
[81.]
P. Nash.
Therapies for axial disease in psoriatic arthritis. A systematic review.
J Rheumatol, 33 (2006), pp. 1431-1434
[82.]
D. van der Heijde, H.S. Baraf, C. Ramos-Remus, A. Calin, A.L. Weaver, M. Schiff, et al.
Evaluation of the efficacy of etoricoxib in ankylosing spondylitis: results of a fifty-two-week, randomized, controlled study.
Arthritis Rheum, 52 (2005), pp. 1205-1215
[83.]
S.J. Jarrett, F. Sivera, L.S. Cawkwell, H. Marzo-Ortega, D. McGonagle, E. Hensor, et al.
MRI and clinical findings in patients with ankylosing spondylitis eligible for anti-tumour necrosis factor therapy after a short course of etoricoxib.
Ann Rheum Dis, 68 (2009), pp. 1466-1469
[84.]
D.D. Gladman, P.J. Mease, P. Healy, P.S. Helliwell, O. Fitzgerald, A. Cauli, et al.
Outcome measures in psoriatic arthritis.
J Rheumatol, 34 (2007), pp. 1159-1166
[85.]
K. Webster, D. Cella, K. Yost.
The Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System: properties, applications, and interpretation.
Health Qual Life Outcomes, 1 (2003), pp. 79
[86.]
P.J. Mease, C.E. Antoni, D.D. Gladman, W.J. Taylor.
Psoriatic arthritis assessment tools in clinical trials.
Ann Rheum Dis, 64 (2005), pp. ii49-ii54
[87.]
S.P. McKenna, L.C. Doward, D. Whalley, A. Tennant, P. Emery, D.J. Veale.
Development of the PsAQoL: a quality of life instrument specific to psoriatic arthritis.
Ann Rheum Dis, 63 (2004), pp. 162-169
[88.]
P.J. Healy, P.S. Helliwell.
Psoriatic arthritis quality of life instrument: an assessment of sensitivity and response to change.
J Rheumatol, 35 (2008), pp. 1359-1361
[89.]
M. Englbrecht, Y. Wang, M. Ronneberger, B. Manger, N. Vastesaeger, D.J. Veale, et al.
Measuring joint involvement in polyarticular psoriatic arthritis: an introduction of alternatives.
Arthritis Care Res (Hoboken), 62 (2010), pp. 977-983
[90.]
D. van der Heijde, J. Sharp, S. Wassenberg, D.D. Gladman.
Psoriatic arthritis imaging: a review of scoring methods.
Ann Rheum Dis, 64 (2005), pp. ii61-ii64
[91.]
V.P. Nell-Duxneuner, T.A. Stamm, K.P. Machold, S. Pflugbeil, D. Aletaha, J.S. Smolen.
Evaluation of the appropriateness of composite disease activity measures for assessment of psoriatic arthritis.
Ann Rheum Dis, 69 (2010), pp. 546-549
[92.]
M. Schoels, D. Aletaha, J. Funovits, A. Kavanaugh, D. Baker, J.S. Smolen.
Application of the DAREA/DAPSA score for assessment of disease activity in psoriatic arthritis.
Ann Rheum Dis, 69 (2010), pp. 1441-1447
[93.]
S. Garrett, T. Jenkinson, L.G. Kennedy, H. Whitelock, P. Gaisford, A. Calin.
A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index.
J Rheumatol, 21 (1994), pp. 2286-2291
[94.]
W.J. Taylor, A.A. Harrison.
Could the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) be a valid measure of disease activity in patients with psoriatic arthritis?.
Arthritis Rheum., 51 (2004), pp. 311-315
[95.]
J.L. Fernandez-Sueiro, A. Willisch, S. Pertega-Diaz, J.A. Tasende, J.C. Fernandez-Lopez, N.O. Villar, et al.
Validity of the bath ankylosing spondylitis disease activity index for the evaluation of disease activity in axial psoriatic arthritis.
Arthritis Care Res (Hoboken), 62 (2010), pp. 78-85
[96.]
L. Eder, V. Chandran, H. Shen, R.J. Cook, D.D. Gladman.
Is ASDAS better than BASDAI as a measure of disease activity in axial psoriatic arthritis?.
Ann Rheum Dis, 69 (2010), pp. 2160-2164
[97.]
R. Queiro, J. Belzunegui, C. Gonzalez, D.J. De, C. Sarasqueta, J.C. Torre, et al.
Clinically asymptomatic axial disease in psoriatic spondyloarthropathy. A retrospective study.
Clin Rheumatol, 21 (2002), pp. 10-13
[98.]
D.D. Gladman, R.D. Inman, R.J. Cook, D. Van der Heijde, R.B. Landewe, J. Braun, et al.
International spondyloarthritis interobserver reliability exercise−the INSPIRE study: I. Assessment of spinal measures.
J Rheumatol, 34 (2007), pp. 1733-1739
[99.]
P.J. Mease.
Assessment tools in psoriatic arthritis.
J Rheumatol, 35 (2008), pp. 1426-1430
[100.]
J. Fransen, C. Antoni, P.J. Mease, W. Uter, A. Kavanaugh, J.R. Kalden, et al.
Performance of response criteria for assessing peripheral arthritis in patients with psoriatic arthritis: analysis of data from randomised controlled trials of two tumour necrosis factor inhibitors.
Ann Rheum Dis, 65 (2006), pp. 1373-1378
[101.]
G. Haberhauer, C. Strehblow, P. Fasching.
Observational study of switching anti-TNF agents in ankylosing spondylitis and psoriatic arthritis versus rheumatoid arthritis.
Wien Med Wochenschr, 160 (2010), pp. 220-224
[102.]
J.M. Berthelot, S. Varin, G. Cormier, L. Tortellier, P. Guillot, J. Glemarec, et al.
25mg etanercept once weekly in rheumatoid arthritis and spondylarthropathy.
Joint Bone Spine, 74 (2007), pp. 144-147
Copyright © 2011. Sociedad Española de Reumatología and Colegio Mexicano de Reumatología
